[3H]retinoic acid.
In 1945, Karrer and Jucker synthesized hepaxanthin by reacting retinol with monoperphthalic acid (Karrer, 1948; Karrer & Jucker, 1950) . The spectral characteristics of the compound led to speculation that hepaxanthin might be a retinol epoxide, but the exact chemical structure was not determined. The 5,6-epoxides of retinyl acetate, retinol and retinal have been synthesized in an analogous fashion and were found to have biological activity equal to retinyl acetate Lakshmanan et al., 1965) . 5,6-Epoxyretinoic acid (John et al., 1967) and methyl 5,6-epoxyretinoate (Morgan & Thompson, 1966) have also been synthesized and both support the growth of vitamin Adeficient rats. However, like retinoic acid, the 5,6-epoxide does not support the visual or reproductive functions of vitamin A. Recently, 5,6-epoxyretinoic acid was isolated from intestinal mucosa of vitamin A-deficient rats after a single 450,ug dose of [3H] retinoic acid (Napoli et al., 1978; McCormick et al., 1978a) , demonstrating that the 5,6-epoxide is a metabolite of retinoic acid in the rat in vivo (Fig. 1) . Since supraphysiological doses of retinoic acid were used to generate sufficient quantities of the metabolite for identification, the synthesis of 5,6-epoxyretinoic acid under physiological conditions remained to be determined. The present report demonstrates that 5,6-epoxyretinoic acid is formed in (Zile & DeLuca, 1968) . Rats were used for metabolism experiments after reaching a weight plateau.
Chemicals and solvents
All-trans-retinoic acid was obtained from Eastman Kodak Co. (Rochester, NY, U.S.A.). [11,12- samples was determined by reverse-phase h.p.l.c. (McCormick et al., 1978b (McCormick et al., , 1979a . 5,6-Epoxyretinoic acid was synthesized as previously described (Morgan & Thompson, 1966; John et al., 1967 Retinoic acid and 5,6-epoxyretinoic acid were batch eluted with 50ml of column solvent. The solvent was evaporated, the residue was dissolved in 5 ml of methanol and applied to a column (1 cm x 15 cm) of DEAE-Sephadex A-25 (hydroxide form). Neutral lipids were eluted with 50 ml of methanol and the charged components were eluted with 50 ml of 0.1 Mammonium acetate in methanol. Ammonium acetate was removed by evaporation of the methanol and resuspension of the residue in acetone. The precipitated salt was removed by filtration. Determination of retinoic acid and 5,6-epoxyretinoic acid by reverse-phase h.p.l.c. Samples recovered from DEAE-Sephadex were chromatographed on a uC18 Bondapak column with a solvent system of 0.01 M-NH4HCO3 in methanol/water (1: 1, v/v). Retinoic acid and 5,6-epoxyretinoic acid were added to each sample to determine the exact elution volume of the compounds in each chromatographic run. The 5,6-epoxide eluted at 80ml and retinoic acid was then eluted by changing the solvent to methanol. 5,6-Epoxyretinoic acid and 1980 5,6-EPOXYRETINOIC ACID retinoic acid are radiochemically pure after reversephase h.p.l.c. in this solvent system. The concentrations of each compound were calculated from the specific radioactivity of the administered retinoic acid.
Results
Time course of appearance of retinoic acid and 5,6-epoxyretinoic acid in intestinal mucosa The total methanol-soluble radioactivity in the mucosa was maximal 3 h after intrajugular administration of 2,ug of [1 1,12-3Hlretinoic acid. In addition, the highest concentration of retinoic acid (5ng/g) and 5,6-epoxyretinoic acid (100pg/g) were detected at the 3h time point. At 7h post injection, mucosal retinoic acid was decreased by 50%. No 5,6-epoxyretinoic acid was detected at 7h (Fig. 3) Tissue distribution of retinoic acid and 5,6-epoxyretinoic acid
The 3 h time point was chosen to study tissue distribution of 5,6-epoxyretinoic acid after administration of physiological levels of [3Hlretinoic acid. The reverse-phase h.p.l.c. profiles of the D1 metabolite fraction (see Fig. 2 ) isolated from several tissues after administration of 9.2,ug of all-trans-retinoic acid is shown in Fig. 4 . Retinoic acid and its 5,6-epoxide were detected in serum, intestinal mucosa, intestinal contents, liver, kidney and testes. In addition, a radioactive peak slightly less polar than the 4-oxo-retinoic acid standard was detected in all tissue extracts. This component was also detected in the mucosa after a single 450,pg dose of [ 1 1,1 2-3lreti-noic acid and designated metabolite 81 (Napoli et al., 1978; McCormick et al., 1978a McCormick et al., , 1979b . It is interesting to note that no 4-oxoretinoic acid, recently identified as a major urinary and faecal metabolite after pharmacological doses of retinoic acid (Hanni et al., 1976; Hanni & Bigler, 1977; Rietz et al., 1974) Fraction no. (Ito et al., 1974; Napoli et al., 1978; McCormick et al., 1978a McCormick et al., ,b, 1979a . In the present study we have examined the biosynthesis of the DI metabolites (Fig. 2) (Fidge et al., 1968; Lippel & Olson, 1968a,b) .
5,6-Epoxyretinoic acid was detected in liver, mucosa, kidney, testis, serum and intestinal contents of vitamin A-deficient rats 3 h after administration of physiological amounts of retinoic acid. The concentration of 5,6-epoxide in the tissues examined was in the 50-250pg/g tissue range, in contrast with the nanogram amounts of unmetabolized retinoic acid. In kidney, mucosa and serum, 5,6-epoxide concentrations were comparable in animals receiving either 2 or 9,ug of retinoic acid, despite a 2-fold increase in the tissue substrate concentration at the higher dosage. However, in liver and testis, the increased substrate concentration is paralleled by increased 5,6-epoxide concentrations. These The amounts of this as yet unidentified metabolite are highest in liver and intestinal contents. Since 5,6-epoxyretinoic acid was detected in all tissues examined, the present data provide no clues to the site(s) of synthesis of this metabolite unless it is indeed made in all tissues in which it was observed. The fact that retinoic acid was present in high concentrations in all tissues where the 5,6-epoxide was detected suggests that this possibility cannot be overlooked. The fact that retinoic acid and 5,6-epoxyretinoic acid are found in the intestinal contents raises the question of the mechanism by which they appear in contents. Their presence could be explained by: (1) sloughing of mucosal cells into the contents fraction during the washing procedure used to separate intestinal tissue from contents; (2) excretion of these compounds via the bile or other mechanism; (3) enterohepatic circulation of the compounds. The data available are compatible with any of the three possible explanations.
In contrast, metabolite 8, was observed only in mucosa, liver, intestinal contents and serum. These data suggest that this metabolite may be circulated in the rat via the enterohepatic circulation. However, the site of synthesis has not yet been located.
Intestine, a known target organ of vitamin A (Johnson et al., 1969; Zile & DeLuca, 1970; DeLuca et al., 1969) , was chosen for further study of the D I metabolite fraction. The time course of the D1 metabolites was studied over a 7 h period after administration of a physiological dose of retinoic acid. The concentration of unmetabolized retinoic acid reached a peak at 3 h and declined to 50% of the maximum concentration by 7 h. The concentration of 5,6-epoxyretinoic acid in mucosa was also highest at 3 h, but in contrast with retinoic acid, none of the epoxide metabolite was detected at 7 h. The rapid disappearance of the 5,6-epoxide from mucosa suggests that it is either rapidly metabolized or excreted by the rat. From these data, it does not appear that a steady-state concentration of 5,6-epoxyretinoic acid is maintained in mucosa unless it is below the detection limits of the present experiments (2 pg/g). The concentration of metabolite 8, in mucosa remained at a constant value (400 pg/g) during the time period studied.
In retinoic acid-repleted rats, decreases in total methanol-soluble radioactivity and in tissue concentrations of [3Hlretinoic acid were noted in mucosa, liver and serum. The observed decreases could be the result of: (1) decreased uptake of [3Hlretinoic acid at the tissue level due to adequate endogenous concentrations of retinoic acid and/or further metabolites in liver and mucosa; (2) accelerated metabolism and excretion of retinoic acid and further metabolites; (3) a combination of the two processes. No 5,6-epoxy-[3Hlretinoic acid was detected in serum, liver or mucosa of retinoic acid-repleted rats. The endogenous concentrations of retinoic acid and 5,6-epoxide in the repleted rats were not determined since a suitable method for measuring low amounts (100pg-5 ng) of non-radioactive metabolites in tissue samples is not yet available. However, assuming that 60% of the retinoic acid supplements are excreted in 24 h (Lippel & Olson, 1 968a,b; Geison & Johnson, 1970) , the maximum dilution of dosed [3Hlretinoic acid would raise detection limits to 20pg/g. Thus although the actual tissue concentrations of retinoic acid and 5,6-epoxide cannot be calculated from these data, it is evident that the amounts of the tritiated compounds are decreased in liver, serum and mucosa in retinoic acid-repleted rats. The observed decrease in 5,6-epoxy[3Hireti-noic acid could be explained by accelerated metabolism or excretion of the metabolite. However, an equally viable alternative is that endogenous 5,6-epoxide may have repressed the synthesis of the 3H-labelled 5,6-epoxide.
Synthetic 5,6-epoxyretinoic acid has 80-100% the biological activity of all-trans-retinoic acid in supporting the growth of vitamin A-deficient rats (John et al., 1967) . In addition, the 5,6-epoxide is equally as effective as retinoic acid in blocking the induction of ornithine decarboxylase activity in mouse epidermis and in preventing the appearance of skin papillomas after dimethylbenzanthracene administration in mice (A. K. Verma, J. L. Napoli, R. K. Boutwell, A. M. McCormick & H. F. DeLuca, unpublished work). Despite the high biopotency of this metabolite established in two quite different vitamin A-responsive test systems, the biological significance of 5,6-epoxyretinoic acid remains uknown.
